Thus, a new meta-analysis was planned to evaluate the benefits and limitations of GLP-1 agonists to address obesity in adolescents without diabetes or any other secondary causes of obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.